Tinostamustine hydrochloride
Based on 5 publication(s) in Google Scholar
Tinostamustine hydrochloride (EDO-S101 hydrochloride) is a compound with anti-multiple myeloma activity and the ability to promote CD38 expression. Tinostamustine hydrochloride enhances the sensitivity of tumor cells to the anti-CD38 monoclonal antibody daratumumab by increasing the acetylation level of histone H3. Tinostamustine hydrochloride can increase the expression of MICA and MICB, thereby activating NK cells. Tinostamustine hydrochloride can significantly delay tumor growth and improve the survival rate of mice.
For research use only. We do not sell to patients.
- CAS No.: 1793059-58-1
- Formula: C19H29Cl3N4O2
- Molecular Weight:451.82
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications Citing Use of MedChemExpress (MCE) Tinostamustine hydrochloride
More
Biological Activity
Chemical Information
-
CAS No. 1793059-58-1
-
Molecular Weight 451.82
-
Formula C19H29Cl3N4O2
-
SMILES
O=C(NO)CCCCCCC1=NC2=CC(N(CCCl)CCCl)=CC=C2N1C.Cl
-
Synonyms
EDO-S101 hydrochloride; NL-101 hydrochloride
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (5)
-
Journal Impact Factor
-
Most Recent
-
Acta Pharmacol Sin
2022 Feb;43(2):457-469. PMID: 33850273 -
Nutrients
Butyrate Protects Barrier Integrity and Suppresses Immune Activation in a Caco-2/PBMC Co-Culture Model While HDAC Inhibition Mimics Butyrate in Restoring Cytokine-Induced Barrier Disruption. [Abstract]2023 Jun 15;15(12):2760. PMID: 37375664 -
Int J Mol Sci
Tinostamustine (EDO-S101) and Its Combination with Celecoxib or Temozolomide as a Therapeutic Option for Adult-Type Diffuse Gliomas. [Abstract]2025 Jan 14;26(2):661. PMID: 39859375 -
Int J Mol Sci
Butyrate Prevents Induction of CXCL10 and Non-Canonical IRF9 Expression by Activated Human Intestinal Epithelial Cells via HDAC Inhibition. [Abstract]2022 Apr 2;23(7):3980. PMID: 35409339 -
Purity & Documentation
References
[1]. Mehrling T, et al. The Alkylating-HDAC Inhibition Fusion Principle: Taking Chemotherapy to the Next Level with the First in Class Molecule EDO-S101. Anticancer Agents Med Chem. 2016;16(1):20-8. [Content Brief]
[2]. Tinostamustine (EDO-S101), an Alkylating Deacetylase Inhibitor, Enhances the Efficacy of Daratumumab in Multiple Myeloma by Upregulation of CD38 and NKG2D Ligands [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)